

We want to hear from you!



Looking to hear from those diagnosed with **breast, colorectal, pancreatic, stomach, or esophagus cancers**

Who are we looking for?

We are looking to speak to patients and caregivers of those who have been diagnosed with cancer (**breast, colorectal, pancreatic, stomach, or esophagus**) and treated with the chemotherapy drug, fluoropyrimidine: 5-FU or capecitabine.

What is the opportunity?

Ontario Health's Quality Division is currently reviewing **DPYD genotype testing**. Let us know your experience with cancer and opinion on the testing. **You do not need to have experience with DPYD testing**. This will help us to make recommendations to the Ministry of Health about whether DPYD testing should be publicly funded.

What is a DPYD genotyping test?

The test is used to identify patients with a DPD deficiency who could experience severe side effects when treated with a chemotherapy drug called fluoropyrimidine.

How you can help:

We will need:

- **30-40 minutes of your time for a telephone interview to share your experiences**
- **Permission to audio record the interview, if possible.**

TO APPLY: Those interested in telephone interview, please contact **Jigna Mistry** through email or phone call (contact information below).

For more information:

Jigna Mistry,

Patient, Caregiver and Public Engagement

(toll-free) 1-866-623-6868 ext. 742

Jigna.Mistry@ontariohealth.ca

Deadline for applications: January 11th, 2021